Studying the Efficacy of Vazonat in Comprehensive Treatment of Patients with Diabetes Mellitus Type 2

Main Article Content

V.I. Pankiv


The objective — to study the effectiveness of Vazonat (meldonium) in patients with diabetes mellitus (DM) type 2 in the comparative 12-week study. Materials and methods. The study involved 55 patients with DM type 2. Patients of the first group in addition to the basic treatment for DM received meldonium (Vazonat, OlainFarm JSC, Latvia) at a dose of 1000 mg/day during 12 weeks. The second group included 25 patients with DM type 2 (8 men and 17 women, average age 60.4 ± 1.9 years), who received only basic therapy of DM. Results. 12-week meldonium therapy as a part of combination therapy for DM type 2 statistically significantly improves the performance of kidney function, as indicated by a significant reduction in the level of microalbuminuria, creatinine and increased glomerular filtration rate in the first group of patients. Inclusion in the treatment regimen of Vazonat in patients with type 2 DM improves morphofunctional parameters of the heart, has additional nephroprotective action, reduces the average values of triglycerides and low-density lipoproteins, as well as glycated hemoglobin levels compared to baseline therapy. Conclusions. Vazonat, combining cardioprotective properties and hypoglycemic effect, is a particularly good choice for comprehensive treatment of patients with impaired glucose metabolism, diabetic nephropathy and heart failure.

Article Details

How to Cite
Pankiv, V. “Studying the Efficacy of Vazonat in Comprehensive Treatment of Patients With Diabetes Mellitus Type 2”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 4.76, July 2016, pp. 80-84, doi:10.22141/2224-0721.4.76.2016.77813.
Clinical Diabetology


International Diabetes Federation. Diabetes Atlas, 7th edition, Brussels, Belgium: International Diabetes Federation, 2015, 143 р.

KorpachevVV,Коrpacheva-ZinychOV,GurinaNM.Estimationofantihypoxicefficiencyofmeldoniuminpatientswithtype 2 diabetesmellitusandmicrovascularviolations.Ukrainiskiymedychnyichasopys. 2015;(108):63-65. Ukrainian.

Klusa V, Beitnere U, Pupure J, Isajevs S, Rumaks J, Svirskis S, Dzirkale Z, Kalvinsh I. Mildronate and its neuroregulatory mechanisms: targeting the mitochondria, neuroinflammation, and protein expression.Medicina (Kaunas). 2013;49(7):301-309.

Pupure J, Isajevs S, Skapare E, Rumaks J, Svirskis S, Svirina D, Kalvinsh I, Klusa V. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule.Neurosci Lett. 2010;470(2):100-105.

Klusa V, Muceniece R, Isajeva S, Isajeva D, Beitnere U, Mandrika I, Pupure J, Rumaks J, Jansone B, Kalvinsh I, Vinters HV. Mildronate enhances learning/memory and changes hippocampal protein expression in trained rats.PharmacolBiochemBehav. 2013;106:68-76.

LobanovaМV, Poletaeva LV, RomaniukSS. Influence of mildronat on the blood glucose level and glycated haemoglobin in patients with type 2 diabetes mellitus. VestnikRossiyskogogosudarstvennogomeditsinskogounivertsiteta. 2008;2(61):37-41. Russian.

StatsenkoМЕ, TurkinaSV, BelenkovaSV. Possibilities of application of mildronate for patients with chronic heart failure,type 2 diabetes mellitus and autonomous cardialneuropathy.Rossiyskiykardiologicheskiyzhurnal. 2009;3(77):69-75.

TopchiyII, DenysenkoVP,Smolkin MG. Role of meldoniumin the holiatry of patients with a diabetic nephropathy and hypertension // Ukrainikiyterapevtychnyyzhurnal. 2014;2:45-50.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>